Deficient immune response following SARS-CoV-2 vaccination in patients with hepatobiliary carcinoma: a forgotten, vulnerable group of patients?
| Autor: | Malte Benedikt Monin, Leona I. Baier, Jens G. Gorny, Moritz Berger, Taotao Zhou, Robert Mahn, Farsaneh Sadeghlar, Christian Möhring, Christoph Boesecke, Kathrin van Bremen, Jürgen K. Rockstroh, Christian P. Strassburg, Anna-Maria Eis-Hübinger, Matthias Schmid, Maria A. Gonzalez-Carmona |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Liver Cancer, Pp 1-1 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2235-1795 1664-5553 |
| DOI: | 10.1159/000529608 |
| Popis: | Background: Data on immune response rates following vaccination for SARS-CoV-2 in patients with hepatobiliary carcinoma (HBC) are rare. However, impaired immunogenicity must be expected due to the combination of chronic liver diseases (CLD) with malignancy and anticancer treatment. Methods: In this prospective, longitudinal study, 101 patients were included, of whom 59 were patients with HBC under anticancer treatment. A cohort of patients with a past medical history of gastrointestinal cancer (GI-cancer), of whom 28.6% had HBC without detectable active tumor disease having been off therapy for at least 12 months served as control. Levels of SARS-CoV-2 anti-spike IgG, surrogate neutralization antibodies (sNAB) and cellular immune responses were compared. In uni- and multivariable subgroup analyses, risk factors for impaired immunogenicity were regarded. Data on rates and clinical courses of SARS-CoV-2 infections were documented. Results: In patients with HBC under active treatment, levels of SARS-CoV-2 anti-spike IgG were significantly lower (2.55 log10 BAU/mL; 95% CI 2.33 to 2.76; p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|